natgillin/translations-raw huggingface dataset:
- Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. 
- redko se lahko pojavijo neobičajni zlomi stegnenice, še posebno pri bolnikih, ki so na dolgotrajnem zdravljenju osteoporoze.
Prevention of skeletal related events in patients with advanced malignancies involving bone Adults and elderly people 
Preprečevanje z okostjem povezanih dogodkov pri bolnikih z napredovalimi malignimi boleznimi, ki zajamejo kosti Odrasli in starejši ljudje
Patients received either 4 mg zoledronic acid or placebo every four weeks for one year. 
4 mg zoledronske kisline bodisi placebo vsake štiri tedne.
Studies with glass bottles, as well as several types of infusion bags and infusion lines made from polyvinylchloride, polyethylene and polypropylene (prefilled with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution), showed no incompatibility. 
Študije s steklenicami, več vrstami vreč za infundiranje in več vrstami infuzijskih sistemov, izdelanih iz polivinilklorida, polietilena in polipropilena (predhodno napolnjenih z 9 mg/ml (0,9-odstotno) raztopino natrijevega klorida ali -odstotno m/v raztopino glukoze), niso pokazale nezdružljivosti.
What Zoledronic Acid Teva is and what it is used for What you need to know before you are given Zoledronic Acid Teva How Zoledronic Acid Teva is given Possible side effects 
Kaj je zdravilo Zoledronska kislina Teva in za kaj ga uporabljamo Kaj morate vedeti, preden vam bodo dali zdravilo Zoledronska kislina Teva Kako se daje zdravilo Zoledronska kislina Teva
- The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line. 
- Raztopino, ki vsebuje zoledronsko kislino, dajemo v obliki ene same 15-minutne intravenske infuzije z ločenim infuzijskim sistemom.
For storage condition after dilution of the medicinal product, see section 6.3. 
Za pogoje shranjevanja po prvem odprtju zdravila glejte poglavje 6.3.
Zoledronic Acid Teva must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. 
Zdravilo Zoledronska kislina Teva smejo predpisovati in dajati bolnikom samo zdravstveni delavci, ki imajo izkušnje z uporabo intravenskih difosfonatov.
Clinical studies in tumour-induced hypercalcaemia (TIH) demonstrated that the effect of zoledronic acid is characterised by decreases in serum calcium and urinary calcium excretion. 
Rezultati kliničnih preskušanj v zdravljenju tumorsko povzročene hiperkalciemije (TIH) Klinične študije hiperkalciemije, povzročene s tumorjem (TIH), so pokazale, da je za učinek zoledronske kisline značilno znižanje serumskega kalcija in zmanjšanje izločanja kalcija z urinom.
What Zoledronic Acid Teva is and what it is used for 
Kaj je zdravilo Zoledronska kislina Teva in za kaj ga uporabljamo
4 x 5 ml vials 
4 x 5 ml viale
To assess the effects of 4 mg zoledronic acid versus pamidronate 90 mg, the results of two pivotal multicentre studies in patients with TIH were combined in a pre-planned analysis. 
Za oceno učinkov 4 mg zolendronske kisline v primerjavi s pamidronatom 90 mg so v vnaprej načrtovani analizi združili rezultate dveh ključnih multicentričnih študij pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH).
- Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs) - Flu-like symptoms including arthritis and joint swelling - Painful redness and/or swelling of the eye. 
- intersticijska bolezen pljuč (vnetje tkiva okoli zračnih mešičkov v pljučih), - simptomi, ki spominjajo na gripo, vključno z artritisom in oteklinami sklepov, - boleča rdečina in/ali oteklina očesa.
How to prepare and administer Zoledronic Acid Teva - To prepare an infusion solution containing 4 mg zoledronic acid, further dilute the Zoledronic Acid Teva concentrate (5 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution. 
Kako pripraviti in dati bolniku zdravilo Zoledronska kislina Teva - Infuzijsko raztopino, ki vsebuje 4 mg zoledronske kisline, pripravite tako, da dodatno razredčite koncentrat zdravila Zoledronska kislina Teva (5 ml) s 100 ml infuzijske raztopine, ki ne vsebuje kalcija ali drugih dvovalentnih kationov.
Patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with Zoledronic Acid Teva outweighs the possible risk. 
Bolnike s tumorsko povzročeno hiperkalciemijo (TIH) in z znaki poslabšanja ledvične funkcije, moramo ustrezno ovrednotiti in pri tem pretehtati, ali možna korist zdravljenja z zdravilom Zoledronska kislina Teva odtehta možno nevarnost.
In the clinical trials, renal deterioration was defined as follows: - For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 μmol/l), an increase of 
V kliničnih preskušanjih so opredelili ledvično poslabšanje takole: - pri bolnikih z normalnim izhodiščnim serumskim kreatininom (< 1,4 mg/dl ali < 124 μmol/l),
- Other medicines that also contain zoledronic acid and which are used to treat osteoporosis and other non-cancer diseases of the bone, or any other bisphosphonate, since the combined effects of these medicines taken together with Zoledronic Acid Teva are unknown. 
- če se zdravite z zdravili, ki tudi vsebujejo zoledronsko kislino in se uporabljajo za zdravljenje osteoporoze in ostalih nerakavih bolezni kosti, ali če jemljete zdravila, ki vsebujejo katere koli druge difosfonate, saj skupni učinki jemanja teh zdravil skupaj z zdravilom Zoledronska kislina
- From a microbiological point of view, the diluted solution for infusion should be used immediately. 
- Z mikrobiološkega stališča je razredčeno raztopino za infundiranje najbolje uporabiti takoj.
In patients who show evidence of renal deterioration during treatment, Zoledronic Acid Teva should be withheld. 
Bolnikom, pri katerih se med zdravljenjem pokažejo znaki poslabšanja ledvične funkcije, je treba zdravilo Zoledronska kislina Teva ukiniti.
Zoledronic acid 8 mg (N=90) 
zoledronska kislina 8 mg (N=90)
For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. 
Pri bolnikih, pri katerih se med difosfonatnim zdravljenjem razvije osteonekroza čeljustnic, lahko stomatološka operacija poslabša stanje.
The hydration status of patients must be assessed prior to and following administration of Zoledronic Acid Teva to ensure that they are adequately hydrated. 
Status hidracije bolnikov mora zdravnik oceniti pred in po dajanju zdravila Zoledronska kislina Teva, da se prepriča, da so ustrezno hidrirani.
In clinical trials performed in patients with tumour-induced hypercalcaemia (TIH), the overall safety profile amongst all three treatment groups (zoledronic acid 4 and 8 mg and pamidronate 90 mg) was similar in types and severity. 
V kliničnih preskušanjih pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH) je bil celotni varnostni profil v vseh treh zdravljenih skupinah (zoledronska kislina 4 in 8 mg in pamidronat 90 mg)
LIST OF EXCIPIENTS Excipients: mannitol, sodium citrate and water for injections. 
Pomožne snovi: manitol, natrijev citrat in voda za injekcije.
- Do not use Zoledronic Acid Teva after the expiry date stated on the vial and carton after EXP. 
- Zdravila Zoledronska kislina Teva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in viali poleg oznake EXP.
Rare (may affect up to 1 in 1,000 people): - Slow heart beat. 
Redki (pojavijo se lahko pri največ 1 do 1.000 bolnikov): - počasno bitje srca,
Intravenous use. 
Način uporabe intravenska uporaba
Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required (see section 4.4). 
Kadar difosfonate dajemo sočasno z aminoglikozidi, kalcitoninom ali diuretiki Henlejeve zanke je priporočljiva previdnost, ker utegnejo imeti navedene učinkovine aditiven učinek, kar bi imelo za posledico nižje koncentracije serumskega kalcija za dalj časa, kot je potrebno (glejte poglavje 4.4).
Other medicinal products containing zoledronic acid as active substances are available for osteoporosis indications and treatment of Paget´s disease of the bone. 
Na voljo so tudi druga zdravila, ki vsebujejo zdravilno učinkovino zoledronska kislina, in se uporabljajo za zdravljenje osteoporoze in Pagetove bolezni kosti.
Your doctor will carry out blood tests before you start treatment with Zoledronic Acid Teva and will check your response to treatment at regular intervals. 
Preden začnete zdravljenje z zdravilom Zoledronska kislina Teva, vam bo zdravnik opravil preiskave krvi in v rednih presledkih preverjal vaš odziv na zdravljenje.
This medicine contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially “sodium-free”. 
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na vialo, kar v bistvu pomeni »brez natrija«.
- Low level of calcium in the blood. 
- nizka koncentracija fosfata v krvi.
- Severe bone, joint and/or muscle pain, occasionally incapacitating. 
− hude bolečine v kosteh, sklepih in/ali mišicah, ki bolnika včasih onesposobijo.
All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with Zoledronic Acid Teva. 
Vsem bolnikom je treba naročiti, naj v času zdravljenja z zdravilom Zoledronska kislina Teva skrbijo za dobro ustno higieno in redno hodijo na preglede k zobozdravniku, v primeru simptomov v ustni votlini, kot so majavost zob, bolečine, otekline ali neceljenje ran ali vnetje, pa naj takoj obvestijo zdravnika.
Uncommon (may affect up to 1 in 100 people): - Pain in the mouth, teeth and/or jaw, swelling or non-healing sores inside the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov): - bolečina v ustih, zobeh in/ali čeljusti, oteklost ali neceljenje ran v ustni votlini ali čeljusti, izcedek, odrevelenost ali občutek pritiska v čeljusti ali majanje zoba, kar so lahko znaki poškodbe kosti v čeljusti (osteonekroze).
Uncommon (may affect up to 1 in 100 people): - Hypersensitivity reactions. 
Občasni (pojavijo se lahko pri največ 1 do 100 bolnikov): - preobčutljivostne reakcije,
Your doctor may recommend a dental examination before you start treatment with Zoledronic Acid Teva. 
Zdravnik vam bo morda svetoval, da pred začetkom zdravljenja z zdravilom Zoledronska kislina Teva opravite zobozdravstveni pregled.
Common (may affect up to 1 in 10 people): - Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/or muscle ache. 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): - glavobol in gripi podoben sindrom, ki ga sestavljajo zvišana telesna temperatura, utrujenost, šibkost, zaspanost, mrazenje in bolečine v kosteh, sklepih in/ali mišicah.
Table 4: Efficacy results (breast cancer and multiple myeloma patients) 
Preglednica 4: Rezultati učinkovitosti (bolnice/bolniki z rakom dojke in multiplim mielomom)
abdominal pain, dry mouth. 
stomatitis, suha usta
Important information about some of the ingredients in Zoledronic Acid Teva 
Pomembne informacije o nekaterih pomožnih snoveh zdravila Zoledronska kislina Teva
Manufacturer Pharmachemie B.V. Swensweg 5 
Izdelovalci Pharmachemie B.V.
Caution is advised when Zoledronic Acid Teva is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5). 
Pri dajanju zdravila Zoledronska kislina Teva skupaj z zdravili, za katera je znano, da povzročajo hipokalciemijo, je potrebna previdnost, saj lahko delujejo sinergistično in povzročijo hudo hipokalciemijo (glejte poglavje 4.5).
What Zoledronic Acid Teva looks like and contents of the pack Zoledronic Acid Teva is supplied as a concentrate for solution for infusion. 
Izgled zdravila Zoledronska kislina Teva in vsebina pakiranja Zdravilo Zoledronska kislina Teva je koncentrat za raztopino za infundiranje.
− As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia). 
− zaradi nizke vrednosti kalcija: napadi krčev, otrplost in tetanija (zaradi hipokalciemije);
Diluted Solution - The readily prepared Zoledronic Acid Teva infusion solution should preferably be used immediately. 
Pripravljena raztopina - Razredčeno raztopino zdravila Zoledroniska kislina Teva je najbolje raztopino za infundiranje uporabiti takoj.
Patients being treated with Zoledronic acid Teva should not be treated with such medicinal products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown. 
Zoledronska kislina Teva ne smejo sočasno prejemati teh zdravil ali katerega koli od drugih difosfonatov, saj učinki kombinacije navedenih učinkovin niso znani.
Zoledronic acid 4 mg (N=86) 
10. dan zoledronska kislina 4 mg (N=86)
• Hypersensitivity to the active substance, to other bisphosphonates or to any of the excipients listed in section 6.1 
4.3 Kontraindikacije - Preobčutljivost na zdravilno učinkovino, na druge difosfonate ali katero koli drugo pomožno snov, navedeno v poglavju 6.1.
Zoledronic Acid Teva should only be resumed when serum creatinine returns to within 10% of baseline. 
Zdravljenje z zdravilom Zoledronska kislina Teva se sme spet začeti šele, ko se serumski kreatinin vrne na vrednost, ki ni za več kot 10 % večja od izhodiščne.
This adverse drug reaction consists of a constellation of symptoms that includes fever, myalgia, headache, extremity pain, nausea, vomiting, diarrhoea arthralgia and arthritis with subsequent joint swelling. 
Ta neželeni učinek zdravila zajema sklop simptomov, ki vključujejo zvišano telesno temperaturo, mialgijo, glavobol, bolečine v okončinah, navzeo, bruhanje, diarejo, artralgijo in artritis, ki povzroči otekline sklepov.
• Breast-feeding (see section 4.6) 
- Dojenje (glejte poglavje 4.6).
Zoledronic Acid Teva treatment should be resumed at the same dose as that given prior to treatment interruption. 
Zdravljenje z zdravilom Zoledronska kislina Teva je treba spet začeti z enakim odmerkom kot ga je bolnik prejemal pred prekinitvijo zdravljenja.
- Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ). 
Teva niso znani, - antiangiogena zdravila (uporabljamo jih pri zdravljenju raka), ker kombinacijo le-teh z zoledronsko kislino povezujejo s povečanim tveganjem za osteonekrozo čeljustnic.
The following properties have been demonstrated in preclinical studies: - In vivo: Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment, making it less conducive to tumour cell growth, anti-angiogenic activity and anti-pain activity. 
- In vivo: Inhibicijo osteoklastne resorpcije kosti, ki spremeni mikrookolje kostnega mozga, tako da je le-to manj ugodno za rast tumorskih celic, protiangiogeno aktivnost in protibolečinsko aktivnost.
The active substance is zoledronic acid. 
- Zdravilna učinkovina je zoledronska kislina.
Common (may affect up to 1 in 10 people): - Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests). 
Takoj povejte zdravniku, če imate katerega od naslednjih resnih neželenih učinkov: Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): - huda okvara ledvic (običajno jo ugotovi zdravnik z določenimi specifičnimi krvnimi preiskavami), - nizka raven kalcija v krvi.
In the clinical programme patients aged 1 to < 3 years received 0.025 mg/kg zoledronic acid (up to a maximum single dose of 0.35 mg) every 3 months and patients aged 3 to 17 years received 0.05 mg/kg zoledronic acid (up to a maximum single dose of 0.83 mg) every 3 months. 
V kliničnem programu so bolniki v starosti od 1 leta do < 3 leta prejeli 0,025 mg/kg zoledronske kisline (do največ 0,35 mg v enkratnem odmerku)
Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria 
astenija, periferni edemi, reakcije na mestu injiciranja (vključujoč bolečino, iritacijo, otekanje, zatrdlino), bolečina v prsih, zvečanje telesne mase, anafilaktična reakcija/šok,
Patients treated with Zoledronic Acid Teva should be given the package leaflet and the patient reminder card. 
Bolnikom, ki prejemajo zdravilo Zoledronska kislina Teva, je treba izročiti navodilo za uporabo in opozorilno kartico za bolnika.
- Zoledronic acid must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein. 
- Zoledronsko kislino vam sme dati samo zdravstveni delavec, ki je usposobljen za intravensko (kar pomeni v veno) dajanje difosfonatov.
The refrigerated solution should then be equilibrated to room temperature before administration. 
Ohlajeno raztopino je treba pred uporabo pustiti, da se ogreje na sobno temperaturo.
Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in viali poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Statistically significant differences are marked (*p<0.05) for between treatment comparisons (4 mg zoledronic acid vs. placebo) 
Povprečne spremembe od izhodišča na BPI lestvici, označene so statistično značilne vrednosti p (*p < 0,05) za primerjavo med obema vrstama zdravljenja (4 mg zoledronska kislina v primerjavi s placebom)
Instructions for preparing reduced doses of Zoledronic Acid Teva: Withdraw the appropriate volume of the liquid concentrate, as follows: - 4.4 ml for 3.5 mg dose 
Navodila za pripravo zmanjšanih odmerkov zdravila Zoledronska kislina Teva: Odvzemite ustrezni volumen tekočega koncentrata, kot sledi:
Do not use this medicine if you notice any particles or discoloration in the solution. 
Ne uporabite raztopine, če je drugačne barve ali so v njej majhni delci.
Dizziness, paraesthesia, dysgeusia, hypoaesthesia, hyperaesthesia, tremor, somnolence 
vrtoglavost, parestezija, disgevzija, hipestezija, hiperestezija, tremor, somnolenca konvulzije, hipestezija in tetanija (zaradi hipokalciemije)
Caution is indicated when Zoledronic Acid Teva is used with other potentially nephrotoxic medicinal products. 
Kadar zdravilo Zoledronska kislina Teva dajemo z drugimi potencialno nefrotoksičnimi zdravili, je potrebna previdnost.
In a third phase III randomised, double-blind trial, 4 mg zoledronic acid or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion. 
NA ne velja za ta primer V tretjem randomiziranem, dvojno slepem preskušanju faze III so pri bolnicah/bolnikih z multiplim mielomom ali rakom dojke z vsaj po eno lezijo v kosteh primerjali zoledronsko kislino 4 mg in 90 mg pamidronata vsake 3 do 4 tedne.
You should not be given Zoledronic Acid Teva: - if you are breast-feeding. 
Zdravila Zoledronska kislina Teva ne smete dobiti: - če dojite.
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 1 x 5 ml vial 
koncentrat za raztopino za infundiranje 1 x 5 ml viala
Zoledronic Acid Teva is not recommended for use in adolescents and children below the age of 18 years. 
Pri otrocih in mladostnikih, ki so stari manj kot 18 let, uporaba zdravila Zoledronska kislina Teva ni priporočena.
Caution is advised when Zoledronic Acid Teva is administered with anti-angiogenic medicinal products as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products. 
Pri uporabi zdravila Zoledronska kislina Teva skupaj z antiangiogenimi zdravili je potrebna previdnost, saj so pri bolnikih, ki so sočasno prejemali navedena zdravila, opažali povečano pogostnost osteonekroze čeljustnic.
Do not mix Zoledronic Acid Teva concentrate with calcium-containing or other divalent cation containing solutions such as lactated Ringer's solution. 
Ne mešajte rekonstituirane raztopine zdravila Zoledronska kislina Teva z raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata.
- Low level of magnesium and potassium in the blood. 
- nizka koncentracija levkocitov in trombocitov, - nizki koncentraciji magnezija in kalija v krvi.
The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. 
1,3 % (pri 51 od 3.862 bolnic), pri bolnicah, ki so prejemale placebo, pa 0,6 % (pri 22 od
Dyspnoea, cough, bronchoconstriction 
dispneja, kašelj, bronhokonstrikcija intersticijska bolezen pljuč
There have been very rare cases of drowsiness and sleepiness with the use of zoledronic acid. 
Ob uporabi zoledronske kisline v zelo redkih primerih prišlo do dremavosti in zaspanosti.
− As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to hypocalcaemia). 
− zaradi nizke vrednosti kalcija: motnje srčnega ritma (aritmija, razvije se zaradi hipokalciemije).
This medicinal product must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line. 
To zdravilo ne smete mešati z infuzijskimi raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata, in jo je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
This resulted in exaggerated pharmacological effects considered to be related to the compound's inhibition of skeletal calcium metabolisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study. 
Prišlo je do poudarjenega farmakološkega delovanja, domnevno zaradi zaviranja presnove kalcija v kosteh, ki je v obdobju okrog poroda povzročalo hipokalciemijo (kar je značilno za celotno skupino difosfonatov), distocijo in predčasno prekinitev študije.
It is especially important that you tell your doctor if you are also taking: - Aminoglycosides (medicines used to treat severe infections), calcitonin (a type of medicine used to treat post-menopausal osteoporosis and hypercalcaemia), loop diuretics (a type of medicine to treat high blood pressure or oedema) or other calcium-lowering medicines, since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low. 
Posebno pomembno je, da zdravniku poveste, če jemljete tudi naslednja zdravila: - aminoglikozide (zdravila, ki jih uporabljamo za zdravljenje težkih okužb), kalcitonin (vrsta zdravila, ki ga uporabljamo za zdravljenje pri postmenopavzalni osteoporozi in hiperkalciemiji),
Zoledronic Acid Teva concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line. 
Koncentrat zdravila Zoledronska kislina Teva se ne sme mešati z infuzijskimi raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata in ga je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
Cardiac arrhythmias and neurologic adverse events (including convulsions, hypoaesthesia and tetany) have been reported secondary to cases of severe hypocalcaemia. 
Poročali so o razvoju aritmij in nevroloških neželenih učinkov (vključno s konvulzijami, hipestezijo in tetanijo), do katerih je prišlo zaradi hude hipokalciemije.
Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing) 
zvišana telesna temperatura, gripi podoben sindrom (z utrujenostjo, okorelostjo, občutkom slabosti in napadi rdečice)